Source-grounded facts extracted from BIOXYTRAN, INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOXYTRAN, INC issued 19,750,001 shares of common stock of warrant to accredited investors for exercise price of $0.12 per share.
“the Company also issued warrants to purchase up to 19,750,001 shares of common stock at an exercise price of $0.12 per share.”
BIOXYTRAN, INC issued 21,071,667 shares of common stock of common stock to accredited investors for $0.055 per share.
“On March 18, 2026, the Company completed the closing of a private placement of unregistered shares of common stock under Securities Purchase Agreements with certain accredited investors pursuant to which the Company issued an aggregate of 21,071,667 shares of common stock at a purchase price of approximately $0.055 per share for aggregate gross proceeds of approximately $1.2 million.”
BIOXYTRAN, INC issued preferred stock.
“The Company approved and filed an amendment to the Certificate of Designation of Convertible Preferred Stock to modify the conversion provisions of the Company’s Preferred Stock.”
BIOXYTRAN, INC: Filed Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock, effective upon filing (effective 2026-02-18).
“In connection with the amendment described above, the Company filed a Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock with the Nevada Secretary of State on February 18, 2026, which became effective upon filing.”
BIOXYTRAN, INC entered into Distribution Agreement with Khoury Medical LTD (effective 2026-02-10).
“On February 10, 2026, Bioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD”
BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.
“the Company engaged Fruci & Associates II, PLLC ("Fruci"), PCAOB ID # 05525, as their successor auditor in order to re-audit the Financial Statements for the years ended December 31, 2023 and 2022.”
BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.
“On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.”
BIOXYTRAN, INC dismissed BF Borgers CPA PC as its auditor.
“On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.”
Dr. Radka Milanova was elected as Director at BIOXYTRAN, INC.
“Effective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased).”
BIOXYTRAN, INC entered into Amended Engagement Letter with WallachBeth Capital LLC valued at Brokerage of three notes totaling $1,165,000, with issuance of 800,000 warrants exercisable at $0.20 (effective 2023-05-08).
“On May 8, 2023, Bioxytran, Inc. (the “Company”) signed an amended engagement letter (the “Engagement Agreement”) with WallachBeth Capital LLC (“WallachBeth”) to brokerage a deal for three (3) of Company’s outstanding Notes, for a total value of one million one hundred sixty-five thousand dollars ($1,165,000).”
BIOXYTRAN, INC entered into Common Stock Closing Agreement with Triton Funds LP valued at Purchase of 1,612,903 shares for $500,000 (approx. $0.31 per share) (effective 2023-06-08).
“On June 8, 2023, Bioxytran, Inc. (the “Company”) entered into a common stock closing agreement (the “Closing Agreement”) with Triton Funds LP (“Triton”). Pursuant to the Closing Agreement, subject to certain conditions set forth in the Closing Agreement, Triton will purchase one million six hundred twelve thousand nine hundred three (1,612,903) shares of the Company’s Common Stock for an amount of five hundred thousand dollars ($500,000), or $0.31 per share (the “Closing Price”).”
BIOXYTRAN, INC engaged BF Borgers CPA PC as its auditor.
“engaged the accounting firm of BF Borgers CPA PC ("BF Borgers") as the Company’s new independent registered public accounting firm.”
BIOXYTRAN, INC dismissed Pinnacle Accountancy Group of Utah as its auditor.
“agreed to dismiss the Company’s independent registered public accounting firm, Pinnacle Accountancy Group of Utah ("Pinnacle"), effective as of March 06, 2023.”
Hana Chen-Walden was elected as Director at BIOXYTRAN, INC.
“The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.”
Henry Esber resigned as Director at BIOXYTRAN, INC.
“Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.